Skip to main content
SpringerLink
Log in

Imiquimod

  • Chapter
European Handbook of Dermatological Treatments

  • 148 Accesses

Abstract

Since its first official approval for use in external genital and perianal warts about 16 years ago, imiquimod has revolutionized not only the therapeutic protocols but also our understanding of the immunogenetic properties of some of the most frequent dermatovenereological disorders. Besides the aforementioned external genital and perianal warts, imiquimod 5 % cream is officially approved for treatment of superficial small (<2 cm) non-facial basal cell carcinoma (BCC) and actinic keratoses on the face and scalp. However, the list of off-label indications continues to expand offering potential cost-effective and more elegant treatment options. The most relevant updates about the use of imiquimod in dermatology and venereology have been briefly summarized in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143:843–5.

    Article  CAS  PubMed  Google Scholar 

  • Ahn MY, Kwon SM, Cheong HH, et al. Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. J Oral Pathol Med. 2012;41(7):540–6.

    CAS  PubMed  Google Scholar 

  • Aldara. Package insert. Revised 03/2013. Available from: http://www.almp.hr/upl/lijekovi/PIL/UP-I-530-09-10-01-451.pdf.

  • Arevalo I, Tulliano G, Quispe A, et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis. 2007;44:1549–4.

    Article  CAS  PubMed  Google Scholar 

  • Babel N, Eibl N, Ulrich C, et al. Development of Kaposi’s sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transp Infect Dis. 2008;10:59–62.

    Article  CAS  Google Scholar 

  • Badgewell C, Rosen T. Treatment of limited extent extramammary Paget’s disease with 5% imiquimod cream. Dermatol Online J. 2006;12(1):22.

    Google Scholar 

  • Barr KL, Konia TH, Fung MA. Lupus erythematosus-like imiquimod reaction: a diagnostic pitfall. J Cutan Pathol. 2011;38(4):346–50.

    PubMed  Google Scholar 

  • Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol. 2002;47:S209–11.

    Article  PubMed  Google Scholar 

  • Berman B, Harrison-Balestra C, Perez OA, et al. Treatment of keloid scars post-shave excision with imiquimod 5% cream: a prospective, double-blind, placebo-controlled pilot study. J Drugs Dermatol. 2009;8:455–8.

    PubMed  Google Scholar 

  • Bernstein DI, Spruance SL, Arora SS, Schroeder JL, Meng TC. Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clin Infect Dis. 2005;41:808–14.

    Article  CAS  PubMed  Google Scholar 

  • Burnett TJ, English JC, Ferris LK. Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses. J Drugs Dermatol. 2010;9(8):1022–4.

    PubMed  Google Scholar 

  • Cação FM, Tanaka V, Messina MC, et al. Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. Dermatol Surg. 2009;35:629–33.

    Article  PubMed  CAS  Google Scholar 

  • Campanelli A, Lubbe J. Erosive cheilitis after application of imiquimod 5% cream. J Eur Acad Dermatol Venereol. 2007;21:1429–30.

    Article  CAS  PubMed  Google Scholar 

  • Celestin Schartz NE, Chevret S, Paz C, et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi’s sarcoma skin lesions: a phase I to II, open-label trial in 17 patients. J Am Acad Dermatol. 2008;58(4):585–91.

    Article  PubMed  Google Scholar 

  • Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines. MMWR. 2010;59:1–110.

    Google Scholar 

  • Chakrabarty AK, Mraz S, Geisse JK, et al. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. J Am Acad Dermatol. 2005;52:35–7.

    Article  PubMed  Google Scholar 

  • Chan MP, Zimarowski MJ. Lupus erythematosus-like reaction in imiquimod-treated skin: a report of 2 cases. Am J Dermatopathol. 2011;33(5):523–7.

    Article  PubMed  Google Scholar 

  • Cohen PR, Schulze KE, Tschen JA, et al. Treatment of extramammary Paget’s disease with topical imiquimod cream: case report and literature review. South Med J. 2006;99:396–402.

    Article  PubMed  Google Scholar 

  • Daayana S, Elkord E, Winters U, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer. 2010;102(7):1129–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Deeths MJ, Chapman JT, Dellavalle RP, et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005;52(2):275–80.

    Article  PubMed  Google Scholar 

  • El Malki K, Karbach SH, Huppert J, et al. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J Invest Dermatol. 2013;133(2):441–51.

    Article  PubMed  CAS  Google Scholar 

  • Erickson C, Miller SJ. Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. Int J Dermatol. 2010;49:482–91.

    Article  PubMed  Google Scholar 

  • Florin V, Desmedt E, Vercambre-Darras S, Mortier L. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Invest New Drugs. 2012;30(4):1641–5.

    Article  CAS  PubMed  Google Scholar 

  • Garland SM. Imiquimod. Curr Opin Infect Dis. 2003;16(2):85–9.

    Article  CAS  PubMed  Google Scholar 

  • Gaspari AA, Tyring SK, Rosen T. Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol. 2009;8(5):467–9.

    Google Scholar 

  • Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004;140(12):1490–5.

    Article  CAS  PubMed  Google Scholar 

  • Grussendorf-Conen EI, Jacobs S, Rubben A, Detlefsen U. Topical 5% imiquimod long-term treatment of cutaneous warts resistant to standard therapy modalities. Dermatology. 2002;205(2):139–45.

    Article  CAS  PubMed  Google Scholar 

  • Ho NT, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol. 2007;56(1):63–8.

    Article  PubMed  Google Scholar 

  • Huang SJ, Hijnen D, Murphy GF, et al. J Invest Dermatol. 2009;129(11):2676–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Husar K, Skerlev M. Molluscum contagiosum from infancy to maturity. Clin Dermatol. 2002;20(2):170–2.

    Article  PubMed  Google Scholar 

  • Imiquimod; Aldara, Zyclara. Drug information provided by gold standard. Available from: https://www.clinicalkey.com/#!/ContentPlayerCtrl/doPlayContent/6-s2.0-2108.

  • Jackson JM, Callen JP. Immunomodulators. In: Bolognia JL, Jorizzo JL, Schaeffer JV, editors. Dermatology. 3rd ed. Beijing: Elsevier Limited; 2012. p. 128, 2131–52.

    Google Scholar 

  • Martínez-González MC, Verea-Hernando MM, Yebra-Pimentel MT, Del Pozo J, Mazaira M, Fonseca E. Imiquimod in mycosis fungoides. Eur J Dermatol. 2008;18(2):148–52.

    PubMed  Google Scholar 

  • Micali G, Dall’Oglio F, Nasca MR. An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts. J Dermatolog Treat. 2003;14(4):233–6.

    Article  CAS  PubMed  Google Scholar 

  • Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21:1–14.

    Article  CAS  PubMed  Google Scholar 

  • Myhre PE, Levy ML, Eichenfield LF, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children. Pediatr Dermatol. 2008;25(1):88–95.

    Article  PubMed  Google Scholar 

  • Naylor MF, Crowsen N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149 Suppl 66:66–70.

    Article  CAS  PubMed  Google Scholar 

  • O’Mahony C, Yesudian PD, Stanley M. Imiquimod use in the genital area and development of lichen sclerosus and lichen planus. Int J STD AIDS. 2010;21(3):219–21.

    Article  PubMed  Google Scholar 

  • Patel GK, Goodwin R, Chawla M, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2006;54:1025–32.

    Article  PubMed  Google Scholar 

  • Peris K, Micantonio T, Fargnoli MC, et al. Imiquimod 5% cream in the treatment of Bowen’s disease and invasive squamous cell carcinoma. J Am Acad Dermatol. 2006;55(2):324–7.

    Article  PubMed  Google Scholar 

  • Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol. 2004;29:15–21.

    Article  CAS  PubMed  Google Scholar 

  • Prins RM, Craft N, Bruhn KW, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006;176(1):157–64.

    Article  CAS  PubMed  Google Scholar 

  • Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol. 2006;155:653–6.

    Article  CAS  PubMed  Google Scholar 

  • Rosen T, Harting M, Gibson M. Treatment of Bowen’s disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg. 2007;33(4):427–31.

    CAS  PubMed  Google Scholar 

  • Schacker TW, Conant M, Thoming C, et al. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother. 2002;46:3243–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schön MP, Schön M. The small-molecule immune response modifier imiquimod-its mode of action and clinical use in the treatment of skin cancer. Expert Opin Ther Targets. 2006;10(1):69–76.

    Article  PubMed  CAS  Google Scholar 

  • Schön MP, Schön M. Imiquimod: mode of action. Br J Dermatol. 2007;157 Suppl 2:8–13.

    Article  PubMed  CAS  Google Scholar 

  • Sheth PB, Landis MN. Topical and intralesional antiviral drugs. In: Wolverton SE, Arlook T, editors. Comprehensive dermatologic drug therapy. 3rd ed. Edinburgh: Elsevier Inc.; 2013. p. 38, 473–80.e3.

    Google Scholar 

  • Shibata S, Tada Y, Asano Y, et al. IL-27 activates Th1-mediated responses in imiquimod-induced psoriasis-like skin lesions. J Invest Dermatol. 2013;133(2):479–88.

    Article  CAS  PubMed  Google Scholar 

  • Skerlev M, Husar K. Mollusca contagiosa. In: Gross G, Tyring SK, editors. Sexually transmitted infections and sexually transmitted diseases. 1st ed. Berlin/New York: Springer; 2011. p. 547–52.

    Chapter  Google Scholar 

  • Suchin KR, Junkins-Hopkins JM, Rook AH, et al. Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arc Dermatol. 2002;138:1137–9.

    Article  Google Scholar 

  • Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114:135–41.

    Article  CAS  PubMed  Google Scholar 

  • Syed TA, Goswami J, Ahmadpour OA, et al. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. J Dermatol. 1998;25:309–13.

    Article  CAS  PubMed  Google Scholar 

  • Theos AM, Cummings R, Silverberg NB, et al. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. Cutis. 2004;74:141–2.

    Google Scholar 

  • Vacarro M, Barbuzza O, Guarneri B, et al. Erosive pustular dermatosis of the scalp following treatment with topical imiquimod for actinic keratosis. Arch Dermatol. 2009;145:1340–1.

    Article  Google Scholar 

  • van Seters M, van Beurden M, ten Kate F, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med. 2008;358:1465–73.

    Article  PubMed  Google Scholar 

  • Vidal D, Matías-Guiu X, Alomar A. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol. 2004;151(3):656–62. Available from: http://www.medscape.com/viewarticle/489949.

    Article  CAS  PubMed  Google Scholar 

  • Wolf IH, Smolle J, Binder B, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol. 2003;139:273–6.

    Article  PubMed  Google Scholar 

  • Zyclara. Package insert. Revised 02/2012. Available from: http://www.zyclaracream.com/files/zyclara_pi.pdf.

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Venereology, Zagreb University School of Medicine and Zagreb University Hospital, Šalata 4, 10000, Zagreb, Croatia

    Mihael Skerlev & Suzana Ljubojević Hadžavdić

  2. Division of Dermatovenereology, General Hospital “Dr Ivo Pedišić”, J.J. Strossmayera 59, 44000, Sisak, Croatia

    Ivana Čulav-Košćak

  3. Department of Pathophysiology, Zagreb University School of Medicine, Kišpatićeva 12, 10000, Zagreb, Croatia

    Maja Sirotković-Skerlev

Authors
  1. Mihael Skerlev
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ivana Čulav-Košćak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suzana Ljubojević Hadžavdić
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maja Sirotković-Skerlev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mihael Skerlev .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Andreas Syggros Hospital University of Athens, Athens, Greece

    Andreas D. Katsambas  & Clio Dessinioti  & 

  2. University of Rome “G. Marconi”, Rome, Italy

    Torello M. Lotti

  3. Centro Studi per la Ricerca Multidisciplinare Rigenerativa (CSRMR), Rome, Italy

    Torello M. Lotti

  4. Unit of Dermatology, University of Pisa, Pisa, Italy

    Angelo Massimiliano D’Erme

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Skerlev, M., Čulav-Košćak, I., Ljubojević Hadžavdić, S., Sirotković-Skerlev, M. (2015). Imiquimod. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D’Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45139-7_143

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45139-7_143

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45138-0

  • Online ISBN: 978-3-662-45139-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation